US kidney care speciailst Evergreen Nephrology announced on Tuesday the appointment of David Young to its board of directors.
Young has served in leadership roles such as CEO of GenesisCare, president & CEO of Physicians Endoscopy Inc and COO of Privia Health Inc. He has also worked in senior-level positions at Smile Brands Inc McKesson Specialty Health and US Oncology Inc.
Young will continue to serve on the boards of GenesisCare Cayman Holdings, GenesisCare UK Ltd and Biocartis Holdings Inc.
Adam Boehler, Evergreen Nephrology executive chairman, said: "Evergreen is at an exciting point in its growth, forming new partnerships with nephrologists nationwide, aligning with new payors, and pioneering cutting-edge research. David's extensive operational, financial and executive leadership in healthcare will be invaluable as we pursue our work of providing exceptional kidney care tailored to each patient's journey."
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline